SERUM LEPTIN IS INCREASED IN GROWTH HORMONE-DEFICIENT ADULTS - RELATIONSHIP TO BODY-COMPOSITION AND EFFECTS OF PLACEBO-CONTROLLED GROWTH-HORMONE THERAPY FOR 1 YEAR
S. Fisker et al., SERUM LEPTIN IS INCREASED IN GROWTH HORMONE-DEFICIENT ADULTS - RELATIONSHIP TO BODY-COMPOSITION AND EFFECTS OF PLACEBO-CONTROLLED GROWTH-HORMONE THERAPY FOR 1 YEAR, Metabolism, clinical and experimental, 46(7), 1997, pp. 812-817
The gene product from the ob gene, leptin, has recently been character
ized in humans, The circulating level of leptin is related to body mas
s index (BMI) and more closely to estimates of total body fat, whereas
visceral fat has been reported to be of minor importance, However, it
is unknown if leptin is directly regulated by hormones that influence
substrate metabolism and body composition. We studied leptin in adult
growth hormone (GH)-deficient (GHD) patients substituted with GH trea
tment for 12 months in a parallel double-blind, placebo-controlled stu
dy. Twenty-seven GHD adults aged 44.9 +/- 1.9 years underwent anthropo
metric measurements for determination of regional and total body fat (
BMI, waist to hip ratio [WHR], computed tomographic [CT] scan, dual-en
ergy x-ray absorptiometry [DEXA] scan, and bioimpedance analysis [BIA]
) before and after 12 months of placebo-controlled GH substitution (2
IU/m(2)) in a parallel design, The same measurements were performed in
42 healthy adults aged 39.1 +/- 1.7 years. The logarithm of serum lep
tin levels correlated positively with abdominal subcutaneous fat and t
otal body fat (BIA and DEXA) in untreated GHD patients and healthy sub
jects. Fasting insulin did not correlate with leptin levels in either
of the groups, After 12 months of GH administration, the body composit
ion of GHD patients was significantly changed with respect to a marked
decrease in body fat, The relations of leptin to the estimates of bod
y fat were maintained, and leptin was furthermore related to BMI and f
asting insulin. In multiple linear regression analyses, additional est
imates of visceral adiposity (intraabdominal fat and maximal anterior-
posterior diameter determined by CT scan) were significant determinant
s of leptin in the healthy subjects, The increase in fasting insulin l
evels during GH substitution correlated negatively with the reduction
in leptin levels (r = -.823, P = ,003), At baseline, leptin levels wer
e increased in the patients compared with controls in both sexes (wome
n, 21.8 +/- 3.3 v 11,3 +/- 1.4 ng/mL, P = .002; men, 8.1 +/- 1,2 v 4.7
+/- 0.7 ng/mL, P =.008). Leptin levels were similar in GHD patients t
reated for 12 months compared with healthy controls for both women and
men (women, 15.9 +/- 2.3 and 11.3 +/- 1.4 ng/mL, P =.163; men, 7.1 +/
- 2.8 and 4.7 +/- 0.7 ng/mL P = .759), In healthy adults and in GHD pa
tients, leptin levels were significantly higher in women than in men (
11.3 +/- 1.4 v 4.7 r 0.7 ng/mL, P <.001;21.8 +/- 3,3 v 8.1 +/- 1.2 ng/
mL, P <.001). Gender remained a significant determinant of leptin leve
ls in several models of multiple linear regression analysis also inclu
ding age, estradiol levels, insulin, and estimates of body fat, We con
clude that leptin is increased but not differently regulated in GHD pa
tients compared with normal subjects, and that leptin levels are close
ly related to estimates of body fat. This relationship is maintained d
uring a decrease in body fat due to GH substitution, Copyright (C) 199
7 by W.B. Saunders Company.